Streptococcus pneumoniae is an important cause of bacterial otitis media, pneumonia, meningitis, and bacteremia [1, 2] . Effective host defense against S. pneumoniae depends on the presence of opsonic anti-capsular polysaccharide (PS) antibodies that trigger phagocytic uptake and killing by polymorphonuclear neutrophils (PMNL) [3] .
parameter for evaluation of the clinical protective efficacy of vaccines [9] [10] [11] .
Receptors for the constant region of antibodies (FcR) play a crucial role in the process of phagocytosis. Two subclasses of the leukocyte IgG receptor (FcgR) family, FcgRIIa (CD32) and FcgRIIIb (CD16), are constitutively expressed on PMNL. Both receptors exhibit genetically determined structural and functional biallelic polymorphisms. The FcgRIIa allelic forms differ by 1 aa in their extracellular region at position 131 (either arginine or histidine: IIa-R-H131) [12] . The allelic forms of FcgRIIIb (IIIb-NA1-NA2 polymorphism) [13] differ by 4 aa and two potential glycosylation sites. Both FcgRIIa and FcgRIIIb molecules can bind human IgG1-and IgG3-containing complexes. However, of the human leukocyte FcgR, only FcgRIIa-H131 can effectively interact with complexed human IgG2 [14] . This isotype represents the main IgG subclass induced by polysaccharide antigens and is important in the defense against encapsulated bacteria [15] [16] [17] [18] [19] [20] . Previous studies have convincingly illustrated the importance of the class IIa IgG receptor for neutrophil phagocytosis of encapsulated bacteria [18, 19] .
Phagocytosis assays for S. pneumoniae are commonly performed with freshly isolated human PMNL. This is both laborious and cumbersome due to donor-to-donor variation of PMNL. There is a vast need for better standardized assays to monitor functional antibody levels in human sera. In the present study, we examined the role of FcgR on PMNL in anti-S. pneumoniae immune defense mechanisms and evaluated the performance of functional assays involving FcgRIIa-transfected cells for monitoring antibody activity of sera from vaccinees.
Methods

Human Sera
Sera from 7 children (aged 0.5-9 years) immunized with 7-valent pneumococcal conjugate vaccine (Lederle Wyeth, Pearl River, NY) and 12 adults immunized with 23-valent pneumococcal polysaccharide vaccine (Pneumovax; Merck Sharp & Dohme, Haarlem, The Netherlands) were collected before and 1 month after immunization. The sera were heat-inactivated at 56ЊC for 30 min. All sera used in this study were collected at the University Hospital for Children in Utrecht.
Monoclonal Antibodies (MAbs)
We used the following anti-FcgR MAbs: anti-hFcgRI (CD64) MAb 22 (mIgG1), anti-hFcgRII (CD32) MAb AT10 (mIgG1, and F(ab ) 2 fragments), and MAb IV3 (mIgG2b; all from Medarex, Annandale, NJ); MAb 41H16 (mIgG2a; gift of B. Longenecker, Edmonton, Canada); and anti-hFcgRIII (CD16) MAb 3G8 (mIgG1 and F[ab ] fragments) (Medarex).
Receptor Expression
The expression level of FcgR was assayed by indirect immune fluorescence using a panel of MAbs, followed by a fluorescein isothiocyanate (FITC)-labeled F(ab ) 2 fraction of goat anti-mouse immunoglobulin antiserum (Tago, Burlingame, CA). Fluorescence was quantitated by FACStar flow cytometer (Becton Dickinson, Lincoln Park, NJ). FcgRIIa expression levels on transfected cells were assayed by direct immune fluorescence using FITC-labeled MAb IV.3 or FITC-labeled MAb AT10. To avoid cytophilic binding of MAb to FcgRI, all incubations were done in the presence of 25% heat-inactivated human serum.
ELISA
Serum IgG1, IgG2, IgG3, and IgG4 anti-pneumococcal serotype 14 levels were quantitated by ELISA [20] . Pre-and postimmunization serum samples were analyzed simultaneously in duplicate. All serum samples were preincubated overnight with excess free common cell wall polysaccharide (CPS) to remove anti-CPS antibodies [21] . A serum sample from a healthy nonvaccinated adult was analyzed in every ELISA run as a control. Microtiter plates (Greiner, Langerthal, Germany) were coated overnight with pneumococcal capsular polysaccharide type 14 (ATCC, Rockville, MD; 10 mg/mL) in saline solution. After being washed (PBS/Tween-20, 0.05% vol/vol), plates were incubated (2 h at 37ЊC) with serial dilutions of sera in PBS, 0.05% Tween-20, 1% bovine serum albumin (vol/vol). Plates were then washed and incubated for 2 h at 37ЊC with peroxidase-labeled subclass-specific murine anti-human IgG1 (MH161-1ME), IgG2 (MH162-1ME), IgG3 (MH163-1, HP6095), and IgG4 (MH164-4, HP6169) MAbs (all from CLB, Amsterdam). After a wash and incubation with substrate for 10-20 min at 37ЊC, absorbance was quantitated (Titertek; Flow Laboratories, Irvine, UK). The antibody concentrations of samples were determined by comparison with human hyperimmune plasma pool [22] and expressed relative to this reference pool (100 U/mL; 100%) assigned for each serotype).
Bacteria
Well-encapsulated S. pneumoniae serotype 14 (ATCC) were grown overnight on blood agar plates and cultured until mid-log phase in Todd Hewitt broth supplemented with 0.5% heat-inactivated horse serum. The capsule was checked by Quellung test with rabbit OMNI serum (Statens Seruminstitut, Copenhagen). Bacteria were harvested by centrifugation, washed twice, resuspended in PBS, and heat-inactivated at 56ЊC for 30 min (to inactivate pneumococcal autolysins). The bacteria were then FITC-labeled [23] , aliquotted, and maintained at Ϫ20ЊC until use.
Cells
PMNL.
Fresh peripheral blood granulocytes were isolated from heparinized venous blood using ficoll-histopaque (Sigma, St. Louis) gradient centrifugation. The PMNL were harvested, and the remaining erythrocytes were removed by hypotonic lysis. Cell viability was 199% as determined by Trypan blue exclusion. Before functional assays, PMNL were washed twice with RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, resuspended, and used immediately. All experiments were done with PMNL lacking FcgRI expression (monitored by FACS analysis with CD64 MAb 22). PMNL from donors heterozygous for FcgRIIa-R-H131 were used in all experiments, unless specified otherwise.
IIA1.6 transfectants. Transfection of IIA1.6 cells was done as previously described [24] . The pcDX vector without insert (sham transfectant) or containing either FcgRIIa-R131 [12] or FcgRIIa-H131 cDNA [12] as insert was linearized with ClaI. These vectors were cotransfected with pRC-CMV (1 mg, linearized with ScaI). For each transfection, 10 mg of cDNA and 10 7 IIA1.6 cells were used. Electroporation equipment (Bio-Rad Laboratories, Hercules, CA) was set at 250 V, 960 mF. Two days after transfection, cells were transferred to geneticin-containing medium and seeded in 24-well plates. After 10 days, each well was checked for FcgRIIa expression by FACS analysis using CD32 MAb AT10.
Wells with FcgRIIa-positive cells were supplemented with IgG1 MAb AT10 and incubated for 30 min at 4ЊC, followed by incubation with rat anti-mouse IgG1-coated Dynabeads (Dynal, Oslo) for 30 min at 4ЊC (head-over-head rotation). FcgRIIa-expressing cells were then positively selected with a magnet (Dynal). After two or three selection rounds with Dynabeads, FcgRIIa-expressing cells were enriched to a ∼95%-positive cell population. Transfectants with high levels of FcgRII expression were then sorted by FACStar (Becton Dickinson), yielding cells with high levels of FcgRIIa expression from which stable clones were obtained by limiting dilution cloning. Expression levels of clones used in this study remained stable during the course of experiments described.
Transfectants were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL pen-icillin, 100 mg/mL streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, and 0.8 mg/mL Geneticin (G418; Life Technologies Gibco BRL, Gaithersburg, MD).
Determination of FcgRIIa Allotypes
The method described by Carlsson et al. [25] was used to genotype FcgRIIa-R-H131 polymorphism on genomic DNA of PMNL and HL-60 cells. Genomic DNA was isolated by Pure-Gene kit (Gentra, Minneapolis) and used in a nested PCR with IIa-R131 and IIa-H131 allele-specific primers. DNA from IIa-R/R131 (RR), IIa-R/H131 (HR), and IIa-H/H131 (HH) persons were included as internal controls. Phenotypic analysis of FcgRIIa-R131 and FcgRIIa-H131 allotypes on PMNL and HL-60 cells was done by quantitative flow cytometry using MAb IV3, which reacts with both FcgRIIa-R131 and IIa-H131 allotype, and MAb 41H16, which selectively binds FcgRIIa-R131 [26] .
Opsonophagocytosis
Opsonophagocytosis assays were done as described earlier [27] with minor changes. In brief, well-encapsulated FITC-labeled S. pneumoniae serotype 14 were opsonized with different concentrations of heat-inactivated human sera (range, 0%-5% vol/vol) by incubation for 30 min at 37ЊC. (In Results, data are with bacteria opsonized with 5% serum, unless specified otherwise.) In agreement with previous work [9] , neutralization of antibodies to pneumococcal CPS showed no effect on bacterial phagocytosis (data not shown). Therefore, no anti-CPS neutralization was performed in serum samples.
After wash steps, opsonized FITC-bacteria were incubated with phagocytic cells in a ratio 30:1 for 45 min at 4ЊC to allow binding of opsonized bacteria. In select experiments, 200 ng/mL cytochalasin D (Sigma) was added to inhibit phagocytosis [27] . No external source of complement was added in the experiments described, except in select experiments in which we used 2% (vol/vol) agammaglobulinemic human serum from a donor with undetectable antipneumococcal anticapsular type 14 antibody (determined by ELISA). After three wash steps, cells were split over two tubes and incubated for 45 min at 4ЊC or 37ЊC.
Some samples were evaluated microscopically for bacterial phagocytosis or distribution of FcgRIIa molecules on transfected cells, using confocal laser scanning microscopy (CLM MRC-1000; BioRad). For phagocytosis evaluation, the remaining cell surfacebound bacteria were detected by incubation (30 min at 4Њ) with tetramethylrhodamine B isothiocyanate (TRITC)-conjugated goat anti-human IgGk/l antiserum (Southern Biotechnology, Birmingham, AL). For evaluation of the distribution of FcgRIIa molecules on transfected cells upon incubation with bacteria, transfectants were incubated with serum-opsonized FITC-labeled S. pneumoniae, washed, and incubated with MAb AT10 (g1 isotype) at 4ЊC for 30 min. After being washed, cells were again incubated (4ЊC, 30 min) with TRITC-conjugated goat anti-mouse IgG1 (Southern Biotechnology).
Most samples were analyzed by flow cytometry; remaining cell surface-bound bacteria were detected by incubation (30 min, 4ЊC) with phycoerythrin (PE)-conjugated goat F(ab ) 2 fragments of antihuman IgG (g-chain-specific; Southern Biotechnology) with 5000 cells analyzed per sample. FITC and PE fluorescence intensities of cells maintained throughout at 4ЊC served as a control for bacterial binding (i.e., 0% phagocytosis). The decrease in PE fluorescence of the FITC-positive cells after incubation at 37ЊC reflected bacterial phagocytosis, which was confirmed microscopically. Dot plot diagrams of FITC and PE fluorescence intensities enabled quantification of FITC-positive cells with decreased PE fluorescence by use of electronic gates [27] . From the drop in the mean PE fluorescence intensity of FITC-positive cells, it was possible to estimate the number of cells that actually internalized bacteria. From the total FITC fluorescence intensity of 5000 cells analyzed in each sample, only FITC fluorescence intensity due to cells with decreased PE fluorescence (bacteria internalized) was used to calculate the mean FITC fluorescence intensity of the whole population of screened cells. The calculated mean FITC fluorescence intensity served as a parameter for the opsonic capacity of human sera.
Statistics
Pearson's product moment correlation coefficient was calculated between opsonophagocytosis activities determined with PMNL and IIA1.6 transfectants. Antibody titers were log 10 converted prior to analysis for linear correlation with opsonic activity. was P ! .05 considered significant in both analyses. Student's t test was used to assess the significance of differences between means. Again, significance was set at . P ! .05
Results
We studied phagocytosis of opsonized S. pneumoniae by a novel fluorescence method that allows discrimination between cell-attached and internalized bacteria. After incubation at 4ЊC (to allow binding of opsonized FITC-labeled S. pneumoniae), temperature was shifted to 37ЊC (enabling phagocytosis) or maintained at 4ЊC (control for cell surface-attached bacteria). Subsequent incubation with PE-conjugated goat F(ab ) 2 fragments of anti-human IgG provided an estimate of cell-bound bacteria. FITC fluorescence enabled detection of total bound or phagocytosed S. pneumoniae, and PE fluorescence assayed nonphagocytosed bacteria. Figure 1A shows dot plot diagrams of FITC and PE fluorescence intensities of PMNL in the presence or absence of an external source of complement. Under both experimental conditions, a comparable drop in the PE fluorescence intensity of FITC-positive cells (gated in R) was observed at 37ЊC, indicating that the addition of human complement did not significantly alter in vitro phagocytosis of serum IgG opsonized S. pneumoniae type 14 by PMNL ( ). n ϭ 4 To confirm that bacterial phagocytosis caused the drop in PE fluorescence of PMNL incubated at 37ЊC, PMNL were incubated with cytochalasin D (a phagocytosis inhibitor) [27, 28] . Similar results were obtained with cells maintained at 4ЊC throughout and with cells incubated with cytochalasin D, confirming that the shift in PE fluorescence intensity at 37ЊC was due to ingestion of bacteria ( , data not shown). n ϭ 3 Phagocytosis of S. pneumoniae was further assessed micro- Table 1 . Anti-pneumococcal type 14-specific IgG1 and IgG2 antibodies in reference sera from adults and children. We next evaluated which PMNL FcgR classes were important for phagocytosis of S. pneumoniae opsonized with human serum antibodies. PMNL were used to assay phagocytosis of S. pneumoniae type 14 opsonized with pooled sera either from adults vaccinated with polysaccharide vaccine or from children vaccinated with pneumococcal conjugate vaccine. Experiments were performed in medium alone or in the presence of saturating amounts of different FcgR-blocking MAb (figure 2).
In the presence of F(ab ) fragments of CD16-blocking MAb 3G8, we observed only a slightly decreased S. pneumoniae type 14 phagocytosis. However, F(ab ) 2 fragments of CD32 MAb AT10 or whole IgG of CD32 MAb IV.3 caused nearly complete inhibition of bacterial phagocytosis. Bacterial phagocytosis was undetectable in the presence of both CD32-and CD16-specific antibodies. Bacterial adherence and therefore bacterial phagocytosis proved absolutely dependent on the presence of serum antibodies (data not shown). These results pointed to a crucial role for FcgRIIa in PMNL phagocytosis of opsonized S. pneumoniae. Previous work demonstrated a polymorphism of this receptor to be of importance for interaction with complexed human IgG2 [14, 18, 19] . We thus assessed the effect of the FcgRIIa polymorphism on phagocytosis of serum-opsonized S. pneumoniae. The phagocytic capacities of PMNL from homozygous FcgRIIa-R131 and IIa-H131 donors were studied with a panel of human sera (from adults or children) with documented pneumococcal type-specific IgG subclass distributions (table 1). PMNL from FcgRIIa-H/H131 subjects were significantly more efficient in phagocytosis of bacteria opsonized with these sera than IIa-R/R131 PMNL ( figure 3) .
FcgRIIa was previously shown capable of mediating phagocytosis of opsonized bacteria and erythrocytes when expressed on murine fibroblasts [29] , IIA1.6 [27] , or COS cells [30] . We stably transfected FcgRIIa-R131 and IIa-H131 in the mouse IIA1.6 B cell/macrophage [31] cell line. These cells are derived from the A20 cell line and lack endogenous murine FcgR (due to a deletion in the 5 end of the FcgRII gene) [31, 32] . Upon transfection with human FcgR, these cells proved capable of IgG-dependent phagocytosis of Staphylococcus aureus [27] . Clones of cells that stably expressed high levels of FcgRIIa-R131 or IIa-H131 were generated. The clones used in the present study exhibited receptor expression levels similar to those on PMNL, as evaluated by FACS analysis ( figure 4A ). Both FcgRIIa-R131-and IIa-H131-expressing IIA1.6 cells were capable of binding and phagocytosis of opsonized S. pneumoniae type 14, as determined by flow cytometry (figure 4B). Furthermore, phagocytosis by IIA1.6 cells proved sensitive to cytochalasin D, similar to that by PMNL ( , data not shown). n ϭ 3 Sham-transfected IIA1.6 cells could not bind serum-opsonized S. pneumoniae ( figure 4C) .
We next tested both types of transfectant cells in parallel with PMNL using our panel of sera (detailed in table 1). No bacterial adherence (FITC-positive cells) was detected with nonopsonized bacteria, confirming this process to be antibody-dependent under our experimental conditions. Allotype-matched FcgRIIa-expressing IIA1.6 cells ( figure 4D ) and PMNL ( figure  3B ) yielded similar results, albeit the signals obtained with transfectants were lower than those achieved with "professional" phagocytes. The FcgRIIa-H131 allotype, as with PMNL, proved the higher phagocytosis activity of cells.
Confocal microscopy was used to visualize the distribution of FcgRIIa molecules on IIA1.6 cells upon incubation with opsonized S. pneumoniae (figure 5A) and to confirm S. pneumoniae phagocytosis by IIA1.6 transfectants (figure 5B).
To further validate the performance of FcgRIIa-H131 transfectants for phagocytosis of S. pneumoniae, we assayed the opsonic activity of 38 human sera in parallel with FcgRIIa-H/ H131 PMNL. Comparable patterns of phagocytosis were obtained with both types of cells with a range of serum concentrations ( figure 6A ).
The 38 sera were from 3 donor groups: (1) 7 children before and after vaccination with conjugate vaccine; (2) 6 IgG1-deficient adults before and after vaccination with the 23-valent polysaccharide vaccine; and (3) 6 adults before and after vaccination with 23-valent polysaccharide vaccine. The serum opsonic activity determined with FcgRIIa-H/H131 PMNL or FcgRIIa-H131 transfectants was highly correlated ( ; r ϭ 0.94 figure 6B ). Importantly, the correlation between PMNL and IIA1.6 cells remained highly significant ( , ) when r 1 0.9 P ! .001 each group of sera was analyzed separately.
The isotype distributions in these sera were determined by ELISA. Only anti-pneumococcal type 14-specific IgG1 and IgG2 were detected; IgG3 and IgG4 titers were very low or undetectable. The relationship between opsonic activity and S. pneumoniae-specific IgG subclass distributions was examined in each serum group. Solely anti-pneumococcal-specific IgG2 antibody levels were significantly correlated with the opsonic activity documented with either PMNL ( ; , P ! .05 r ϭ 0.77 , , for serum groups 1, 2, and 3, respectively) r ϭ 0.72 r ϭ 0.89 or IIA1.6 transfectants ( , , , , for P ! .05 r ϭ 0.80 r ϭ 0.71 r ϭ 0.91 serum groups 1-3, respectively).
Discussion
Host protection against invasive pneumococcal disease is mainly dependent on bacterial opsonization by anti-capsular antibodies that facilitate bacterial phagocytosis. At present, human neutrophils are considered a good read-out model to assess the presence of functional antibodies in human sera. A versatile and uniformly standardized phagocytosis assay, however, is not yet available. The reproducible use of PMNL turned out to be complicated because of significant interlaboratory and donorto-donor variabilities. In the present study, we document that a genetically determined structural and functional polymorphism of an Fcg receptor on PMNL represents an important factor in this variability.
We used a novel double-fluorescent flow cytometric method to assess antibody-mediated S. pneumoniae phagocytosis. Our method shares similarities with some previously described assays [19, 28, 33, 34] but offers the advantage that it solely measures antibody-mediated bacterial phagocytosis. Internalization as assessed in the present study was sensitive to temperature and cytochalasin D as predicted for bona fide phagocytosis [28] . Our assay system enables a clear discrimination between attached and internalized bacteria and allows quantitative analysis of ingestion rates. Under our experimental conditions, phagocytosis of serumopsonized S. pneumoniae type 14 by human PMNL was independent of the presence of complement ( figure 1A ). This is in good agreement with previous reports on group B streptococci and S. pneumoniae [19, 20, 35] . Blocking studies with antiFcgR MAb identified FcgRIIa (CD32) on PMNL as essential for the phagocytosis of opsonized S. pneumoniae. This was observed with both sera from adults and from children (with relatively high levels of anti-pneumococcal type-specific IgG1) (figure 2). Conversely, FcgRIIIb (CD16) appeared to play only a minor role in bacterial phagocytosis, confirming earlier data [35] [36] [37] [38] [39] [40] . Previous studies reported a central role of FcgRIIa in phagocytosis of IgG2-opsonized particles [18, 19] . In this study, we observed that the FcgRIIa polymorphism quantitatively determines phagocytosis of serum-opsonized S. pneumoniae. In addition, FcgRIIa-H131-bearing cells proved more sensitive for determining functional differences between pre-and postimmune sera ( figure 3) .
The myeloid human HL-60 cell line was recently proposed as an alternative to PMNL in serum-opsonized S. pneumoniae phagocytosis assays. However, unlike PMNL, the phagocytic activity of differentiated HL-60 cells was highly complementdependent, in agreement with previous reports [10, 11] , and was low in our hands (data not shown). HL-60 cells expressed only FcgRIIa-R131, which may (at least partially) explain these results and, furthermore, compromises its suitability for assessing the opsonic capacity of anti-polysaccharide antibodies that are predominantly of the human IgG2 isotype [41, 42] .
The better performance of FcgRIIa-H131 in phagocytosis of S. pneumoniae was confirmed with stably FcgRIIa-transfected IIA1.6 cells. Although bacterial phagocytosis by transfectants was quantitatively lower than that by PMNL, as would be predicted for "nonprofessional" phagocytic cells, their accuracy to assay opsonic antibody levels was as high as with PMNL. Moreover, the results obtained with PMNL and transfectants showed a high correlation with sera from both adults and children (figure 6).
Our data, together with clinical data on pediatric otitis-prone and sinusitis-prone patients with normal IgG1 and low IgG2 anti-pneumococcal antibodies [16, 20] , are consistent with the belief that IgG2 represents the main opsonin (even in sera from children vaccinated with pneumococcal conjugate vaccine) in conferring clinical protection against pneumococcal infection. In good agreement with this model, only the levels of typespecific anti-PS IgG2 correlated with opsonic activities in our panel of 38 sera. Although relevant opsonic activity of IgG1 cannot be ruled out (because of the low levels of type-specific PS-IgG1), the present data demonstrate not only the importance of IgG2 for opsonophagocytosis of S. pneumoniae but also establish a central role for FcgRIIa in this important immune defense mechanism.
In conclusion, this study supports the importance of FcgRIIa in the defense against encapsulated bacteria, such as S. pneumoniae. Our data further demonstrate that FcgRIIa-transfected cells, which can easily be propagated in vitro, represent an excellent read-out model for testing opsonic antibodies directed against S. pneumoniae in human sera.
